Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial - Miao, Yan; Ottenbros, Stefan A.; Laverman, Goos D.; Brenner, Barry M.; Cooper, Mark E.; Parving, Hans-Henrik; Grobbee, Diederick E.; Shahinfar, Shahnaz; de Zeeuw, Dick; Lambers Heerspink, Hiddo J. (Hypertension (Dallas, Tex. 1979), 2011)
Keywords: Angiotensin II Type 1 Receptor Blockers - administration & dosage; Antihypertensive agents; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular system; Creatinine - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - physiopathology; Diabetic Nephropathies - etiology; Diabetic Nephropathies - physiopathology; Diabetic Nephropathies - prevention & control; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate - drug effects; Humans; Hypertension - blood; Hypertension - complications; Hypertension - drug therapy; Losartan - administration & dosage; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Risk Factors; Time Factors; Treatment Outcome; Uric Acid - blood; Endocrinopathy; Type 2 diabetes; Imidazole derivatives; Tetrazole derivatives; Prognosis; Peptide hormone; Non peptide compound; Cardiovascular disease; angiotensin receptor blocker; Octapeptide; Losartan; type 2 diabetes mellitus; serum uric acid; Angiotensin II; Kidney disease; Hypertension; Urinary system disease; Metabolic diseases; Uric acid; Nephropathy; Treatment; Biphenyl derivatives; Antihypertensive agent; Sartan derivatives; Angiotensin antagonist; diabetic nephropathy